Piper Sandler analyst Matt O’Brien raised the firm’s price target on Beta Bionics (BBNX) to $32 from $26 and keeps an Overweight rating on the shares. The firm notes the company reported another impressive quarter of results that beat across the board. Key highlights from today’s print included strong new patient starts that were much higher than expected, and a larger portion of which coming from the pharmacy that should drive robust top-line growth in 2026-plus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics Reports Strong Q3 Growth and Raises Guidance
- Beta Bionics reports Q3 EPS (33c), consensus (41c)
- Beta Bionics raises FY25 revenue view to over $96.5M from $88M-$93M prior
- Beta Bionics up 13% at $27.39 after Q3 results and guidance raise
- Beta Bionics’ iLet Experience Study: A Game-Changer in Diabetes Management?